NOV 17, 202648 MINS READ
Acetyl Hexapeptide-8 comprises a precisely ordered sequence of six amino acid residues: Ac-Glu-Glu-Met-Gln-Arg-Arg-NH₂, where the N-terminus is acetylated (Ac-) and the C-terminus is amidated (-NH₂) to enhance metabolic stability and membrane permeability 116. The molecular architecture incorporates two glutamic acid (Glu) residues providing anionic character at physiological pH, one methionine (Met) residue susceptible to oxidation under oxidative stress, one glutamine (Gln) contributing hydrogen-bonding capacity, and two arginine (Arg) residues conferring cationic properties and facilitating electrostatic interactions with anionic cell membrane components 16. The acetylation at the N-terminus eliminates the positive charge of the α-amino group, reducing immunogenicity and proteolytic degradation, while C-terminal amidation prevents carboxypeptidase cleavage, collectively extending the peptide's biological half-life in topical formulations 515.
The three-dimensional conformation of Acetyl Hexapeptide-8 in aqueous solution exhibits a flexible extended structure with localized β-turn propensity near the Met-Gln dipeptide segment, as inferred from circular dichroism spectroscopy and molecular dynamics simulations 16. The presence of the thioether-containing methionine residue at position 3 introduces a hydrophobic patch critical for membrane insertion and interaction with lipid bilayers, facilitating transdermal delivery 10. The dual arginine motif at positions 5-6 mimics the polybasic region of SNAP-25 (residues 180-206), enabling competitive binding to syntaxin and synaptobrevin within the SNARE complex, thereby disrupting vesicle fusion and neurotransmitter exocytosis 116.
Key structural parameters include:
The methionine residue represents a critical vulnerability, as oxidation to methionine sulfoxide (Met-SO) under UV exposure or peroxide contamination reduces bioactivity by 60–75% within 48 hours at 40°C 13. Formulation strategies incorporating antioxidants (e.g., tocopherol, ascorbic acid derivatives) and maintaining pH 4.5–6.5 are essential to preserve structural integrity 1113.
Recent crystallographic studies have identified five distinct polymorphic forms of Acetyl Hexapeptide-8, each exhibiting unique X-ray powder diffraction (XRPD) patterns, solubility profiles, and thermodynamic stability 12. These polymorphs arise from differential hydrogen-bonding networks, molecular packing arrangements, and hydration states during crystallization.
Form A and Form B are characterized by enhanced solubility in 1,2-pentanediol, a common lipophilic solvent in cosmetic formulations 1. Form B demonstrates superior dissolution kinetics, achieving Acetyl Hexapeptide-8 concentrations up to 2,160 ppm in 1,2-pentanediol at 25°C, compared to <1 ppm for conventional lyophilized powder 1. XRPD analysis of Form B reveals characteristic 2θ peaks at 4.478°, 6.458°, 17.740°, 19.233°, 20.227°, 23.034°, and 26.947° (±0.2°), indicative of a monoclinic unit cell with space group P2₁ 1. Differential scanning calorimetry (DSC) shows a melting endotherm at 142–145°C for Form B, with an enthalpy of fusion (ΔHf) of 78 ± 3 kJ/mol 1.
The preparation of Form B involves dissolving Acetyl Hexapeptide-8 in a mixed solvent system (water/ethanol/acetonitrile, 40:30:30 v/v/v) at 50°C, followed by slow cooling to 5°C at 0.2°C/min under nitrogen atmosphere, and aging for 12–18 hours to promote nucleation and crystal growth 1. Filtration through a 0.22 μm PTFE membrane and vacuum drying at 35°C for 24 hours yield Form B crystals with >98.5% purity (HPLC) and <0.8% methionine oxidation-related impurities 113.
Form C, Form D, and Form E exhibit superior oxidative stability in oil-based formulations compared to Forms A and B 2. XRPD patterns for Form C display principal 2θ peaks at 4.478°, 6.458°, 8.104°, 12.902°, 13.363°, 13.936°, 14.334°, 15.374°, 16.383°, 17.740°, 18.454°, 19.233°, 20.227°, 20.93°, 22.72°, 23.034°, 23.958°, 25.869°, 26.660°, 26.947°, 28.327°, 32.867°, 33.279°, 34.128°, 34.66°, 38.67°, 43.190°, and 48.01° (±0.2°) 2. Thermogravimetric analysis (TGA) indicates <0.5% weight loss below 100°C, confirming anhydrous character, and onset of decomposition at 185°C 2.
Stability testing under accelerated conditions (40°C/75% RH for 6 months) demonstrates that oil-soluble formulations prepared with Forms C, D, or E retain >92% Acetyl Hexapeptide-8 content, whereas Form B-based formulations retain only 78–82%, and lyophilized powder formulations degrade to <50% 2. This enhanced stability is attributed to reduced exposure of the methionine residue to aqueous oxidants and tighter molecular packing in the crystalline lattice, as evidenced by reduced accessible surface area (ASA) calculated via molecular modeling 2.
Preparation protocols for Forms C–E involve crystallization from ternary solvent systems (e.g., isopropanol/hexane/ethyl acetate) with controlled supersaturation ratios (σ = 1.5–2.0) and seeding with pre-formed nuclei to direct polymorph selection 2. Post-crystallization annealing at 60°C for 4 hours under vacuum further stabilizes the crystal lattice 2.
Solid-phase peptide synthesis remains the predominant method for laboratory- and pilot-scale production of Acetyl Hexapeptide-8, employing Fmoc (9-fluorenylmethoxycarbonyl) chemistry on Rink Amide resin to generate the C-terminal amide 47. The synthesis proceeds via stepwise coupling of protected amino acids in reverse sequence: Fmoc-Arg(Pbf)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Met-OH, Fmoc-Glu(OtBu)-OH, and Fmoc-Glu(OtBu)-OH, where Pbf = 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl, Trt = trityl, and OtBu = tert-butyl ester 416.
Rink Amide-AM resin (loading capacity 0.6–0.8 mmol/g) is swelled in N,N-dimethylformamide (DMF) for 30 minutes, followed by Fmoc deprotection using 20% piperidine in DMF (2 × 10 min) 47. UV monitoring at 301 nm (Fmoc-piperidine adduct) confirms >99% deprotection efficiency 7. The resin is washed sequentially with DMF (3×), dichloromethane (DCM, 3×), and DMF (3×) to remove residual piperidine 4.
Coupling reactions employ a 3-fold molar excess of Fmoc-amino acid, activated with modified N-hydroxyphthalimide (p-dimethylquinone-modified NHPI) and N,N'-diisopropylcarbodiimide (DIC) in DMF at 25°C for 2 hours 7. This modified condensing agent enhances coupling efficiency to >99.2% per cycle, reducing deletion sequences (<0.5% total) and racemization (<0.1% D-isomer formation) compared to conventional HBTU/HOBt systems 7. Kaiser test (ninhydrin assay) or chloranil test (for proline/secondary amines) verifies coupling completion 47.
For challenging couplings (e.g., Fmoc-Gln(Trt)-OH to Met), double coupling with 1.5 equivalents of amino acid and extended reaction time (4 hours) ensures >98.5% yield 4. Microwave-assisted SPPS at 75°C for 5 minutes per coupling cycle reduces synthesis time by 40% while maintaining product purity 7.
Following assembly of the hexapeptide chain, the N-terminal Fmoc group is removed, and acetylation is performed using acetic anhydride (10 equiv.) and N,N-diisopropylethylamine (DIPEA, 15 equiv.) in DMF for 30 minutes at 25°C 47. The acetylated peptide-resin is washed and treated with a cleavage cocktail comprising trifluoroacetic acid (TFA)/triisopropylsilane (TIS)/water/ethanedithiol (EDT) (92.5:2.5:2.5:2.5 v/v/v/v) for 3 hours at 25°C 416. This optimized cleavage system minimizes methionine oxidation (<0.8% Met-SO) and arginine alkylation (<0.3%) 13.
The crude peptide is precipitated in cold diethyl ether (10× volume), collected by centrifugation (4,000 rpm, 10 min, 4°C), and washed three times with ether to remove scavengers and TFA 4. Lyophilization yields crude Acetyl Hexapeptide-8 with 75–85% purity (HPLC) 47.
A novel purification strategy employs silica gel modified with N-(benzo[d]thiazole-2-ylmethyl)acrylamide and methyl 2-acrylamido-2-methoxyacetate as stationary phase modifiers, enhancing selectivity for Acetyl Hexapeptide-8 over deletion sequences and oxidized impurities 4. The crude peptide (dissolved in 0.1% TFA/water) is loaded onto a column (2.5 cm × 30 cm) and eluted with a gradient of acetonitrile (8–40% over 25 min) in 0.1% aqueous TFA at 10 mL/min, monitored at 220 nm 45. The target peak (retention time 18.2 ± 0.3 min) is collected, concentrated under reduced pressure, and lyophilized to afford Acetyl Hexapeptide-8 with >98.0% purity, <0.05% deletion sequences, and <0.8% Met-SO 413.
Alternatively, preparative reversed-phase HPLC on a C₁₈ column (250 mm × 21.2 mm, 10 μm) using a linear gradient of acetonitrile (12–38% over 30 min) in 0.1% TFA achieves baseline separation of Acetyl Hexapeptide-8 from related peptides, with recovery yields of 68–75% 56.
Liquid-phase peptide synthesis offers advantages for kilogram-scale production, including reduced solvent consumption, simplified purification, and elimination of resin costs 16. The LPPS strategy for Acetyl Hexapeptide-8 involves convergent synthesis of three dipeptide fragments—Ac-Glu(OtBu)-Glu(OtBu)-OH, H-Met-Gln(Trt)-OH, and H-Arg(Pbf)-Arg(Pbf)-NH₂—followed by sequential coupling to form the tetrapeptide and hexapeptide 16.
Fragment 1 (Ac-Glu(OtBu)-Glu(OtBu)-OH): Fmoc-Glu(OtBu)-OH (1.0 equiv.) is coupled to H-Glu(OtBu)-OtBu (1.05 equiv.) using DIC (1.1 equiv.) and HOBt (1.1 equiv.) in DCM at 25°C for 4 hours 16. After Fmoc deprotection with 20% piperidine in DMF, acetylation with acetic anhydride/DIPEA affords Ac-Glu(OtBu)-Glu(OtBu)-OtBu. Selective hydrolysis of the C-terminal tert-butyl ester using 5% TFA in DCM (30 min, 0°C) yields Ac-Glu(OtBu)-Glu(OtBu)-OH in 82% isolated yield 16.
Fragment 2 (H-Met-Gln(Trt)-OH): Fmoc-Met-OH is coupled to H-Gln(Trt)-OtBu, followed by Fmoc
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| SHENZHEN READLINE BIOTECHNOLOGY CO. LTD. | Oil-based anti-aging cosmetic formulations including essence oils, makeup removers, and foundation products requiring lipophilic peptide delivery systems. | Oil-Soluble Acetyl Hexapeptide-8 (Polymorphic Form B) | Achieved acetyl hexapeptide-8 concentration up to 2160 ppm in 1,2-pentanediol with enhanced solubility in lipophilic systems, solving the insolubility issue of conventional lyophilized powder in oil-based formulations. |
| SHENZHEN READLINE BIOTECHNOLOGY CO. LTD. | Long-term stable oil-soluble anti-wrinkle cosmetics requiring extended shelf life under accelerated aging conditions and oxidative stress environments. | Acetyl Hexapeptide-8 Polymorphic Forms C/D/E | Retained over 92% peptide content after 6 months at 40°C/75% RH with reduced methionine oxidation (<0.8%), demonstrating superior oxidative stability compared to Form B (78-82% retention) in lipophilic formulations. |
| 杭州信海医药科技有限公司 | High-purity peptide production for pharmaceutical-grade cosmetic raw materials requiring minimal deletion sequences and oxidation byproducts. | Solid-Phase Synthesized Acetyl Hexapeptide-8 | Achieved >98.5% purity with <0.8% methionine oxidation-related impurities through optimized SPPS protocol using modified silica gel chromatography with N-(benzo[d]thiazole-2-ylmethyl)acrylamide modifiers. |
| 浙江湃肽生物有限公司南京分公司 | Large-scale peptide synthesis for cosmetic ingredient manufacturing requiring high coupling efficiency and minimal racemization in SPPS processes. | Acetyl Hexapeptide-8 via Modified NHPI Condensation | Utilized p-dimethylquinone-modified N-hydroxyphthalimide as condensing agent achieving >99.2% coupling efficiency per cycle with <0.1% D-isomer racemization, reducing synthesis time by 40% with microwave assistance. |
| 汉肽生物医药集团有限公司 | Industrial-scale peptide production for cost-effective cosmetic ingredient supply requiring reduced solvent usage and simplified purification workflows. | Liquid-Phase Synthesized Acetyl Hexapeptide-8 | Employed convergent fragment condensation strategy synthesizing three dipeptide units with 82% isolated yield, reducing organic solvent consumption and production costs for kilogram-scale manufacturing. |